Heart Decompensation Clinical Trial
Official title:
Comparison of High VErsus Low Positive End-Expiratory Pressure in Mechanically Ventilated Patients With Acute Heart Failure (HELP-AFH) : Open-label Randomized Controlled Multi-center Pilot Study
Little is known about optimal level of positive end-expiratory pressure (PEEP) in patiens who recieved invasive mechanical ventilation for acute decompensated heart failure. We therefore sought to compare clinical outcome according to low versus high PEEP.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | April 30, 2024 |
Est. primary completion date | July 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: 1. Subject who was diagnosed with congestive heart failure and objective evidence of pulmonary congestion (pulmonary edema on simple chest radiography or positive B-line on lung ultrasonography AND elevated B-type natriuretic peptide or N-terminal pro-brain natriuretic peptide level) as a reason for invasive mechanical ventilation 2. Age over 19 years old 3. Subject who agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the clinical site. Exclusion Criteria: 1. Subject who are on mechanical circulatory support (ECMO, intra-aortic balloon pump, VAD) at the time of randomization 2. Subject who has cardiac abnormality that requires emergent or urgent percutaneous or surgical valvular procedure 3. Subject who are on vasoactive or inotropic agents at least moderate dose defined as vasoactive-inotropic score >10 4. Isolated preload-dependent cardiac dysfunction (isolated right ventricular failure, right ventricular infarction, constrictive pericarditis, cardiac tamponade, severe pulmonary hypertension without LV dysfunction) 5. Predominant right ventricular failure defined as following; clinical evidence of right ventricular failure by attending physician's discretion including hepatojugular reflux, Kussmaul sign, cardiac liver cirrhosis, hepato/splenomegaly, acites, thronmbocytopenia, etc. 6. Subject who are not on mechanical ventilation before open heart surgery 7. Subject who received unwitness cardiopulmonary rescucitation (CPR) or witness CPR lasting more than 30 minutes 8. Subject who was already diagnosed or is suspected to have hypertophic cardiomyopathy with significant left ventricular outflow tract (LVOT) obstruction 9. Subject with intracranial hemorrahge or ischemic stroke at the time of randomization 10. Subject with irreversible neurologic damage or irreversible hepatic failure 11. Invasive mechanical ventilation lasting more than 24 hours preceding endotracheal intubation 12. Subject with underlying chronic obstructive pulmonary disease (GOLD classification III or IV) or restrictive pulmonary disease (e.g. interstitial lung disease) 13. Subject with impaired consciousness that can not perform self coughing and need suction to maintain adequate airway patency 14. Pregnant and/or lactating women 15. Subject with life expectancy less than a year 16. Subject who is not suitable to enrollment by investigator's discretion |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ventilator-free day at 28-day | Starting at the day of randomization, and the days on non-invasive ventilation do not count. Successful extubation is defined as at least 24 hours wihtout reintubation independent of invasive assisted ventilation in survivor. Non-survivor within 28 days: ventilator-free day counted as 0, ventilator-free day among only survivor at 28-day will be counted for primary endpoint. | up to 28-day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05747820 -
Multiparametric Assessment of Cardiac Congestion in Outpatient Worsening Heart Failure
|
||
Recruiting |
NCT02051985 -
Early-start Exercise Training in Subacute Heart Failure
|
N/A | |
Terminated |
NCT02859636 -
Pronostic Value of Endothelial Dysfunction in Heart Failure
|
N/A | |
Completed |
NCT00813202 -
An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure
|
Phase 3 | |
Withdrawn |
NCT00166010 -
Effects of Nesiritide in Pediatric Patients With Heart Failure
|
N/A | |
Completed |
NCT00364416 -
Longitudinal Registry for Advanced Heart Failure Patients
|
N/A | |
Completed |
NCT00366639 -
Registry for Acute Decompensated Heart Failure Patients
|
N/A | |
Completed |
NCT00288730 -
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
|
Phase 3 | |
Completed |
NCT03515980 -
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
|
Phase 1 | |
Completed |
NCT00475852 -
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
|
Phase 3 | |
Completed |
NCT00510601 -
Treating Congestive Heart Failure Using a Device to Remove Cholesterol
|
Phase 0 | |
Completed |
NCT00364325 -
Registry for Acute Decompensated Heart Failure Patients Admitted to the ER
|
N/A | |
Recruiting |
NCT04703504 -
RAndomized Controlled Trial of a Multiple INtervention proGram to Decrease Heart Failure Rehospitalization
|
N/A | |
Withdrawn |
NCT02649998 -
Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF
|
N/A | |
Not yet recruiting |
NCT02324400 -
Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00259038 -
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
|
Phase 2 | |
Completed |
NCT00271557 -
A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood Vessels
|
Phase 3 | |
Completed |
NCT03730961 -
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
|
Phase 2 | |
Completed |
NCT06255418 -
Big Data to Assess the Healthcare and Health Outcomes Burden of Acute Coronary Syndromes Complicated With Heart Failure
|
||
Terminated |
NCT04198779 -
Interest of the Smartphone Application "MonCÅ“ur" in the Follow-up of Patients With Heart Failure
|
N/A |